Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) insider Barbara White bought 1,389 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were bought at an average price of $7.20 per share, for a total transaction of $10,000.80. Following the transaction, the insider now directly owns 185,548 shares in the company, valued at $1,335,945.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Barbara White also recently made the following trade(s):
- On Thursday, March 14th, Barbara White acquired 4,638 shares of Corbus Pharmaceuticals stock. The shares were acquired at an average price of $6.47 per share, for a total transaction of $30,007.86.
NASDAQ CRBP opened at $7.37 on Tuesday. Corbus Pharmaceuticals Holdings Inc has a 1 year low of $4.50 and a 1 year high of $9.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.78 and a quick ratio of 2.45. The firm has a market capitalization of $455.09 million, a PE ratio of -7.52 and a beta of 2.12.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Corbus Pharmaceuticals by 5,967.8% in the 4th quarter. Barclays PLC now owns 9,041 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 8,892 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Corbus Pharmaceuticals by 72,906.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,681 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 11,665 shares in the last quarter. Prospera Financial Services Inc bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter worth $97,000. Cetera Advisor Networks LLC bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter worth $98,000. Finally, Metropolitan Life Insurance Co. NY grew its stake in shares of Corbus Pharmaceuticals by 357.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,973 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 13,265 shares in the last quarter. Hedge funds and other institutional investors own 35.19% of the company’s stock.
Several research firms have weighed in on CRBP. BidaskClub downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. HC Wainwright restated a “buy” rating and set a $24.00 price objective on shares of Corbus Pharmaceuticals in a report on Friday, May 10th. Zacks Investment Research upgraded shares of Corbus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. ValuEngine upgraded shares of Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 21st. Finally, Jefferies Financial Group began coverage on shares of Corbus Pharmaceuticals in a report on Friday, April 5th. They set a “buy” rating and a $18.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Corbus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $23.59.
ILLEGAL ACTIVITY NOTICE: “Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Purchases 1,389 Shares of Stock” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://dakotafinancialnews.com/2019/05/21/insider-buying-corbus-pharmaceuticals-holdings-inc-crbp-insider-purchases-1389-shares-of-stock.html.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.
Further Reading: Dollar Cost Averaging
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.